Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations.

Komocsar WJ, Blackbourne JL, Halstead CA, Winstead CJ, Wierda D.

J Immunotoxicol. 2016;13(1):7-19. doi: 10.3109/1547691X.2014.994793. Epub 2015 Sep 4.

PMID:
25585959
2.

Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendations.

Collinge M, Burns-Naas LA, Chellman GJ, Kawabata TT, Komocsar WJ, Piccotti JR, Shenton J, Wierda D.

J Immunotoxicol. 2012 Apr-Jun;9(2):210-30. doi: 10.3109/1547691X.2012.661486. Epub 2012 Mar 19. Review.

PMID:
22428536
3.

Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs.

Piccotti JR, Lebrec HN, Evans E, Herzyk DJ, Hastings KL, Burns-Naas LA, Gourley IS, Wierda D, Kawabata TT.

J Immunotoxicol. 2009 Mar;6(1):1-10. doi: 10.1080/15476910802656440.

PMID:
19519157
4.

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.

Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D.

Regul Toxicol Pharmacol. 2009 Jul;54(2):164-82. doi: 10.1016/j.yrtph.2009.03.012. Epub 2009 Apr 2.

PMID:
19345250
5.

Preclinical immunogenicity testing for recombinant therapeutic proteins.

Smith HW, Wierda D.

J Immunotoxicol. 2005 Oct 1;2(4):203-10. doi: 10.1080/15476910500362911.

PMID:
18958675
6.

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.

Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA.

J Immunol Methods. 2004 Jun;289(1-2):1-16.

PMID:
15251407
7.

A predictive F344 rat immunotoxicology model: cellular parameters combined with humoral response to NP-CgammaG and KLH.

Smith HW, Winstead CJ, Stank KK, Halstead BW, Wierda D.

Toxicology. 2003 Dec 15;194(1-2):129-45.

PMID:
14636702
8.

Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions.

Adkinson NF Jr, Essayan D, Gruchalla R, Haggerty H, Kawabata T, Sandler JD, Updyke L, Shear NH, Wierda D; Health and Environmental Sciences Institute Task Force.

J Allergy Clin Immunol. 2002 Mar;109(3):S461-78.

PMID:
11897992
9.

Immunogenicity of biopharmaceuticals in laboratory animals.

Wierda D, Smith HW, Zwickl CM.

Toxicology. 2001 Feb 2;158(1-2):71-4. Review.

PMID:
11164995
10.

Can host resistance assays be used to evaluate the immunotoxicity of pharmaceuticals?

Wierda D.

Hum Exp Toxicol. 2000 Apr;19(4):244-5. No abstract available.

PMID:
10918515
11.

Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?

Black LE, Green JD, Rener J, Dayan A, Cavagnaro JA, Spindler P, Bussiere JL, Bouchard P, Inoue T, Thomas PT, Essayan DM, Gillett NA, Hart TK, Hastings K, House RV, Latta D, Liminga U, Treacy G, Wierda D.

Hum Exp Toxicol. 2000 Apr;19(4):205-7. No abstract available.

PMID:
10918508
12.

The selective estrogen receptor modulator, raloxifene: a segment II/III delivery study in rats.

Buelke-Sam J, Cohen IR, Wierda D, Griffey KI, Fisher LF, Francis PC.

Reprod Toxicol. 1998 May-Jun;12(3):271-88.

PMID:
9628551
13.

Immunogenicity of tissue plasminogen activators in rhesus monkeys: antibody formation and effects on blood level and enzymatic activity.

Zwickl CM, Hughes BL, Piroozi KS, Smith HW, Wierda D.

Fundam Appl Toxicol. 1996 Apr;30(2):243-54.

PMID:
8812272
14.
15.
16.

Age-related changes in production of interleukin-7 (IL-7) by murine long-term bone marrow cultures (LTBMC).

Updyke LW, Cocke KS, Wierda D.

Mech Ageing Dev. 1993 Jun;69(1-2):109-17.

PMID:
8377525
17.

Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys.

Zwickl CM, Cocke KS, Tamura RN, Holzhausen LM, Brophy GT, Bick PH, Wierda D.

Fundam Appl Toxicol. 1991 Feb;16(2):275-87.

PMID:
2055359
18.

Environmentally related disorders of the hematologic and immune systems.

Luster MI, Wierda D, Rosenthal GJ.

Med Clin North Am. 1990 Mar;74(2):425-40. Review.

PMID:
2181213
19.

Bone marrow stromal cell bioactivation and detoxification of the benzene metabolite hydroquinone: comparison of macrophages and fibroblastoid cells.

Thomas DJ, Sadler A, Subrahmanyam VV, Siegel D, Reasor MJ, Wierda D, Ross D.

Mol Pharmacol. 1990 Feb;37(2):255-62.

PMID:
2154673
21.
22.

Macrophage regulation of myelopoiesis is altered by exposure to the benzene metabolite hydroquinone.

Thomas DJ, Reasor MJ, Wierda D.

Toxicol Appl Pharmacol. 1989 Mar 1;97(3):440-53. Erratum in: Toxicol Appl Pharmacol 1989 Jun 15;99(2):376.

PMID:
2609342
23.
24.

Chlorphentermine suppresses the phosphatidylinositol pathway in concanavalin A-activated mouse splenic lymphocytes.

Sauers LJ, Wierda D, Reasor MJ.

Immunopharmacol Immunotoxicol. 1988;10(1):1-19.

PMID:
3361070
25.

Hydroquinone inhibits bone marrow pre-B cell maturation in vitro.

King AG, Landreth KS, Wierda D.

Mol Pharmacol. 1987 Dec;32(6):807-12.

PMID:
3501069
26.
27.
28.

Chlorphentermine-induced alterations in the response of human lymphocytes to mitogens.

Sauers LJ, Wierda D, Walker ER, Reasor MJ.

Biochem Pharmacol. 1986 Oct 15;35(20):3651-4. No abstract available.

PMID:
3768049
29.
30.

Modulation of stromal cell function in DBA/2J and B6C3F1 mice exposed to benzene or phenol.

Gaido KW, Wierda D.

Toxicol Appl Pharmacol. 1985 Dec;81(3 Pt 1):469-75.

PMID:
4082195
31.

In vitro effects of benzene metabolites on mouse bone marrow stromal cells.

Gaido K, Wierda D.

Toxicol Appl Pharmacol. 1984 Oct;76(1):45-55.

PMID:
6484990
32.

Partial characterization of bone marrow hemopoiesis in mice after cisplatin administration.

Wierda D, Matamoros M.

Toxicol Appl Pharmacol. 1984 Aug;75(1):25-34.

PMID:
6540492
33.

Midtrimester prenatal diagnosis of achondrogenesis.

Johnson VP, Yiu-Chiu VS, Wierda DR, Holzwarth DR.

J Ultrasound Med. 1984 May;3(5):223-6. No abstract available.

PMID:
6726882
34.
35.

Uridine transport in concanavalin A- and lipopolysaccharide-activated mouse lymphocytes.

Wierda D, Pazdernik TL.

Biochem Pharmacol. 1981 Dec 15;30(24):3295-303. No abstract available.

PMID:
7326038
36.

Immunotoxicity in C57BL/6 mice exposed to benzene and Aroclor 1254.

Wierda D, Irons RD, Greenlee WF.

Toxicol Appl Pharmacol. 1981 Sep 30;60(3):410-7. No abstract available.

PMID:
6794184
37.

Relationship between benzene metabolism and toxicity: a proposed mechanism for the formation of reactive intermediates from polyphenol metabolites.

Irons RD, Greenlee WF, Wierda D, Bus JS.

Adv Exp Med Biol. 1981;136 Pt A:229-43. No abstract available.

PMID:
7344458
38.

Toxicity of platinum complexes on hemopoietic precursor cells.

Wierda D, Pazdernik TL.

J Pharmacol Exp Ther. 1979 Dec;211(3):531-8.

PMID:
512918
39.

Suppression of spleen lymphocyte mitogenesis in mice injected with platinum compounds.

Wierda D, Pazdernik TL.

Eur J Cancer. 1979 Aug;15(8):1013-23. No abstract available.

PMID:
315875
40.

Effects of cyclophosphamide on hemic precursor cells in mouse bone marrow and spleen.

Wierda D, Pazdernik TL.

J Immunopharmacol. 1979;1(3):357-76.

PMID:
553112
41.

Iatrogenic congenital goiter and hypothyroidism with respiratory distress in a newborn.

Melvin GR, Aceto T Jr, Barlow J, Munson D, Wierda D.

S D J Med. 1978 Oct;31(10):15-9. No abstract available.

PMID:
279993

Supplemental Content

Loading ...
Support Center